At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.
Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.
B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.
The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.
Experts analyze adjuvant therapy based on preoperative responses. The discussion unveils standard practices, recent KATHERINE trial data, and considerations for residual disease, offering profound insights…
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
